Prof. Dr. Volker Schirrmacher veröffentlicht zwei wegweisende Übersichtsartikel zur Immuntherapie
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKCancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis
/in International Publications, IOZK Veröffentlichungen /von 2020-03-16 / Biomedicines 2020 Mar;8(3)New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-03-06 / Biomedicines 2020 Mar;8(3)Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
/in International Publications, IOZK Veröffentlichungen /von 2020-03-01 / J Immunother Cancer 2020 03;8(1)Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2019-08-30 / Biomedicines 2019 Aug;7(3)Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2019-04-01 / Anticancer Res 2019 Apr;39(4):2043-2051From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
/in International Publications, IOZK Veröffentlichungen /von 2018-12-10 / Int J Oncol 2019 Feb;54(2):407-419International Journal of Oncology: „Von der Chemotherapie zur biologischen Therapie“, Prof. Dr. Volker Schirrmacher
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKBiological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group
/in Brain Tumors in Children, International Publications, IOZK Veröffentlichungen /von 2018-08-01 / Lancet Oncol 2018 08;19(8):e419-e428
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
- Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
- A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma